While genetics play a significant role, research increasingly points to oxidative stress as a primary driver of follicle aging
Currently approved delivery methods include: Subcutaneous injection : The most common route, using pre-filled pens for once-weekly (semaglutide, dulaglutide) or once-daily (liraglutide) administration Oral tablets : Semaglutide (Rybelsus) is the only FDA-approved oral GLP-1 medication, utilizing absorption-enhancing technology No transdermal patch formulation has received FDA approval for GLP-1 delivery
Regulation of hepatic glutathione synthesis: Current concepts and controversies
Some people may regain weight after stopping the medication
Researchers are still learning about their other potential uses, and more market growth is expected
In the phase 3 REDEFINE 1 trial, the combination of cagrilintide and semaglutide yielded a mean 20% reduction in body weight over 68 weeks in adults with overweight or obesity, significantly outperforming placebo and either agent alone